How to Improve Solubility and Dissolution of Irbesartan by Fabricating Ternary Solid Dispersions: Optimization and In-Vitro Characterization

The purpose of this study is to improve the solubility and dissolution of a poorly soluble drug, Irbesartan, using solid dispersion techniques. For that purpose, different polymers such as Soluplus®, Kollidon® VA 64, Kolliphor® P 407, and Polyinylpyrrolidone (PVP-K30) were used as carriers at different concentrations to prepare solid dispersion formulations through the solvent evaporation method. In order to prepare binary dispersion formulations, Soluplus® and Kollidon® VA 64 were used at drug: polymer ratios of 1:1, 1:2, 1:3, and 1:4 (w/w). Saturation solubility of the drug in the presence of used carriers was performed to investigate the quantitative increase in solubility. Dissolution studies were performed to explore the drug release behavior from the prepared dispersions. Additionally, the characterization of the prepared formulations was carried out by performing DSC, SEM, XRD, and FTIR studies. The results revealed that among binary systems, K4 formulation (Drug: Kollidon® VA 64 at ratio of 1:4 w/w) exhibited optimal performance in terms of increased solubility, drug release, and other investigated parameters. Furthermore, ternary dispersion formulations of the optimized binary formulation were prepared with two more polymers, Kolliphor® P 407 and Polyvinylpyrrolidone (PVP-K30), at (Drug: Kollidon® VA 64:ternary polymer) ratios of 1:4:1, 1:4:2, and 1:4:3 (w/w). The results showed that KPVP (TD3) exhibited the highest increase in solubility, as well as dissolution rate, among ternary solid dispersion formulations. Results of solubility enhancement by ternary solid dispersion formulations were also supported by FTIR, DSC, XRD, and SEM analysis. Conclusively, it was found that the ternary solid dispersion-based systems were more effective compared to the binary combinations in improving solubility as well as dissolution of a poorly soluble drug (Irbesartan).


Introduction
High-throughput screening techniques and combinatorial chemistry have discovered many new compounds as therapeutic agents that possess poor solubility. In recent years, 40-70% of newly discovered drugs have been found to be poorly soluble [1]. A majority of these newly discovered compounds are abandoned at the beginning of the drug development process due to their very low solubility. Therefore, there is a need to overcome these poor solubility issues in order to improve bioavailability and therapeutic effect [2].
A majority of drugs are administered orally as this route provides the easiest method of administration and maximum patient compliance, however, this route also presents many issues. Poor bioavailability due to low solubility of a drug is one of the major hurdles involved
Polymeric solutions of various concentrations (1%, 2%, 3%, and 4% w/v) were formulated in distilled water and supersaturated solutions of these solutes were prepared by adding an excess amount of drug to each falcon tube. These falcon tubes containing supersaturated solutions were positioned in a shaker at 37 • C for 72 h. After centrifugation (4000 rpm for 20 min), these samples were filtered using a 0.45 µm syringe filter. After appropriate dilution, absorbance of each sample was taken at 253 nm using a UV spectrophotometer. Gelucire ® 50/13 solubility was taken at lower concentrations due to its insolubility in water at higher concentration [20].
The appropriate quantity of Irbesartan (approx. 1 g) was dissolved in adequate volume (20 mL) of methanol. The selected carrier was also dissolved in 20 mL methanol separately under constant stirring. These two solutions were mixed together by sonication for 10 min in order to have uniform mixing. Solvent evaporation was carried out using a rotary evaporating apparatus (RE-100 Pro, Scilogex, CT, USA) at 45 • C. The product obtained was dried at 40 • C for 24 h. After pulverization, the dried product was passed through a sieve of mesh No. 80. The dried powder was stored in a tightly closed bottle with desiccating agents for future use [21]. For ternary solid dispersion, prepared binary solid dispersion was dissolved in methanol (30 mL) and the selected carrier was also dissolved in 20 mL methanol separately. These two solutions were mixed together with the help of sonication. Further preparation steps were the same as for binary solid dispersion preparation. Steps involved in preparation of binary and ternary solid dispersions are presented diagrammatically in Figure 2.

Solubility Studies
Solubility was determined by adding pure drug and solid dispersion formulations separately in falcon tubes containing either 0.1 N HCl (1.2 pH) or a phosphate buffer of pH 6.8. These samples were vortexed to prepare supersaturated solution and then placed

Solubility Studies
Solubility was determined by adding pure drug and solid dispersion formulations separately in falcon tubes containing either 0.1 N HCl (1.2 pH) or a phosphate buffer of pH 6.8. These samples were vortexed to prepare supersaturated solution and then placed in a shaker (SWB 15, Thermo-scientific, Waltham, MA, USA) for 72 h at 37 • C. Then, centrifugation was performed at speed of 5000 rpm for 20 min. After proper dilution and filtration of supernatant, analysis was carried out with the help of a UV-visible spectrophotometer (CE-7400S, Cecil, Cambridge, UK) at 253 nm [22].

Dissolution Studies
Dissolution behavior of pure drug and solid dispersion formulations were studied using USP apparatus II (DT 70, Pharma Test, Hainburg, Germany). This study was conducted Pharmaceutics 2022, 14, 2264 6 of 20 using 900 mL of 0.1 N HCl (pH 1.2) and a phosphate buffer of pH 6.8 at 37 • C with stirring speed 100 rpm. Solid dispersion containing 10 mg of API was placed in each dissolution vessel. A 5.0 mL sample aliquot was taken at different time intervals (0, 5,15,30,45,60,90, and 120 min through a 0.45 µm Millipore filter. After withdrawal of a sample aliquot, an equivalent amount of freshly prepared dissolution medium was added to maintain sink conditions. Analysis was carried out with a UV-visible spectrophotometer (CE-7400S, Cecil, Cambridge, UK) at 253 nm [21].

Drug Content and Yield
To determine drug content, an amount of solid dispersion containing 10 mg of drug substance was added to 10 mL of solvent (methanol) and sonicated until the formulation was completely dissolved. After filtration, the UV-visible spectrophotometry technique was used at 253 nm (lambda max) and the amount of drug was determined from the calibration curve.
The following formula was used to calculate % drug contents: % Drug content = calculated drug content/theoretical drug content × 100 In order to determine % yield, there was need to determine the weight of dried solid dispersions (W1) obtained from prepared batches and the initial weight of drug and polymer/s (W2).
The following formula was used to calculate % yield:

Kinetic Model Analysis
Drug release data was fitted into various release models in order to understand the release mechanism using DD solver software.
The equation for zero order is given below. This equation is used to describe concentration independent drug release. where Q = percent of the drug released at time (t), k p is Peppas constant, and n is the release exponent which is used to understand the release mechanism [23] ( Table 2). SEM was performed to reveal the surface characteristics of pure Irbesartan and solid dispersion samples by using an electron microscope (Nova-Nano-450, FEI, Hillsboro, OR, USA). Adhesive tape was used to mount the prepared samples onto the carbon tail ends, after which they were coated with an alloy made up of gold and palladium. Atmospheric pressure was maintained at 0.25 Torr using an ion sputter coater and finally the samples were placed in the scanning chamber [24].

Powder X-ray Diffraction (PXRD)
Changes in drug crystalline structure were determined using an X-ray Diffractometer (JDX3522, Japan). PXRD was carried out by placing samples in an X-ray diffraction device and exposing them to varied angles (4 • to 50 • ) 2θ with scanning speed maintained at 1 • /min [25].

FTIR Analysis
FTIR spectroscopy studies were performed using an FTIR spectrophotometer (Agilent scientific Instruments, Santa Clara, CA, USA) to identify drug substance and to characterize major interactions between API and polymers. Samples were mixed with potassium bromide in a glass mortar and then pressed to prepare potassium bromide discs. Scans were run from 500 to 4000 cm −1 with a resolution power of 1 cm −1 [26].

Differential Scanning Calorimetry (DSC)
DSC thermograms of drug, polymers, and formulations were obtained using a thermal analyzer (SDT Q600, V20.9 Build 20, TA instruments, New Castle, DE, USA). An amount of 5 mg of test substance was kept on a DSC pan made up of aluminum. The temperature to start the test was 25 • C. The temperature was raised by maintaining a speed of 10 • C/min, with a temperature upper limit of 350 • C or T m of the substance. Nitrogen gas flow was maintained at a speed of 30 mL/min [27].

Screening Study
All hydrophilic polymers showed an increase in solubility compared to pure drug in the screening study. The results of the screening study are shown in Table 3. Based on these results, two polymers, namely Soluplus ® and Kollidon ® VA 64, were selected to prepare binary solid dispersions, as these polymers showed the highest increase in solubility.

Solubility Studies
The solubility of pure drug in distilled water, pH 6.8 phosphate buffer, and 0.1 N HCl (pH 1.2) was 10.84 ± 1.079 µg/mL, 19.78 ± 1.56 µg/mL, and 30.72 ± 2.59 µg/mL, respectively. The results of the solubility studies of the prepared formulations are represented in Figure 3. They revealed that the K 4 formulation exhibited the highest saturation solubility (754.08 ± 1.70 µg/mL in 0.1 N HCl and 540.97 ± 1.57 µg/mL in pH 6.8 phosphate buffer) in the case of binary solid dispersions. However, KPVP (TD 3 ) ternary solid dispersion was found to have a saturation solubility of 820.93 ± 3.26 µg/mL and 924.71 ± 0.98 µg/mL in pH 6.8 phosphate buffer and 0.1 N HCl, respectively, which was the maximum increase in solubility among all the prepared ternary solid dispersions. This maximum increase in solubility could be linked to the complete transformation of the crystalline form of the drug into its amorphous form in KPVP (TD 3 ) formulation.
a: Solubility (µg/mL) in respective carrier concentration. b: Insoluble in water.

Solubility Studies
The solubility of pure drug in distilled water, pH 6.8 phosphate buffer, and 0.1 N (pH 1.2) was 10.84 ± 1.079 µg/mL, 19.78 ± 1.56 µg/mL, and 30.72 ± 2.59 µg/mL, respecti The results of the solubility studies of the prepared formulations are represented in F 3. They revealed that the K4 formulation exhibited the highest saturation solubility (7 ± 1.70 µg/mL in 0.1 N HCl and 540.97 ± 1.57 µg/mL in pH 6.8 phosphate buffer) in the of binary solid dispersions. However, KPVP (TD3) ternary solid dispersion was foun have a saturation solubility of 820.93 ± 3.26 µg/mL and 924.71 ± 0.98 µg/mL in pH phosphate buffer and 0.1 N HCl, respectively, which was the maximum increase in bility among all the prepared ternary solid dispersions. This maximum increase in bility could be linked to the complete transformation of the crystalline form of the into its amorphous form in KPVP (TD3) formulation.

Dissolution Studies
The results revealed that the pure drug showed 46.03 ± 0.141% release in 0.1 N and 22.31 ± 0.169% release in pH 6.8 phosphate buffer after 2 h. It was noticed that du first 30 min, the drug release was 11.00 ± 1.49% in 6.8 pH phosphate buffer and 36 0.915% in 0.1 N HCl. Overall, all the prepared formulations showed an increase in release compared to pure drug. This could be attributed to the transformation of the talline drug into its amorphous form, reduced particle size, and increased wetting [22 In addition, Soluplus ® -based binary solid dispersions showed increased drug rel probably due to the maintenance of supersaturation which might result from interm ular bonding between API and Soluplus ® (Figure 4). Noticeably, Soluplus ® -based

Dissolution Studies
The results revealed that the pure drug showed 46.03 ± 0.141% release in 0.1 N HCl and 22.31 ± 0.169% release in pH 6.8 phosphate buffer after 2 h. It was noticed that during first 30 min, the drug release was 11.00 ± 1.49% in 6.8 pH phosphate buffer and 36.55 ± 0.915% in 0.1 N HCl. Overall, all the prepared formulations showed an increase in drug release compared to pure drug. This could be attributed to the transformation of the crystalline drug into its amorphous form, reduced particle size, and increased wetting [22,28]. In addition, Soluplus ® -based binary solid dispersions showed increased drug release, probably due to the maintenance of supersaturation which might result from intermolecular bonding between API and Soluplus ® (Figure 4). Noticeably, Soluplus ® -based solid dispersions provided decreased drug release with increasing Soluplus ® concentration. This may be due to the fact that Soluplus ® possesses swelling properties, which may decrease drug release due to the limited diffusion of drug through the swelled polymer [29,30]. The binary system prepared with Kollidon ® VA 64 (K 4 ) was further selected for the preparation of ternary system as it provided the highest drug release of 71.21 ± 0.364% and 79.75 ± 0.094% in pH 6.8 phosphate buffer and 0.1 N HCl (pH 1.2) after 120 min, respectively ( Figure 5). This maximum increase in solubility and dissolution rate might be associated with sustained supersaturation, formation of nanoparticles during dissolution, crystal nucleation, and growth inhibition by Kollidon ® VA 64 (polymer shows adsorption on drug particles). Another possible mechanism involved in enhancing the solubility of this polymer could be the formation of intermolecular bonding, especially hydrogen bonding between carbonyl functional group of pyrrolidone and vinyl acetate [29] In the case of ternary systems, the formulation KP407 (TD 3 ) exhibited drug release of 82.46 ± 0.082% and 93.20 ± 0.076% in pH 6.8 phosphate buffer and 0.1 N HCl (pH 1.2), respectively, after 120 min, and the formulation KPVP (TD 3 ) showed drug release of 87.31 ± 0.805% and 97.60 ± 0.887% in pH 6.8 phosphate buffer and 0.1 N HCl, respectively, after 120 min. The increase in solubility and drug release in the case of Kolliphor ® P 407-based ternary dispersion might be linked to the surfactant nature of this polymer ( Figure 6). Kolliphor ® P 407 is composed of ethylene oxide and propylene oxide blocks, which are responsible for self-assembly into micelles in aqueous media, thus leading to solubilization of the drug. The mechanism by which PVP-K30 increased drug release is most likely the maintenance of supersaturation resulting from the crystal growth inhibition potential of PVP. Hydrogen bonding between PVP and the weakly basic drug may be another reason for the increased solubility as well as dissolution [29,31].
Based on the results of solubility and dissolution studies, KPVP (TD 3 ) ternary solid dispersion formulation was considered as the optimized formulation ( Figure 7). spectively ( Figure 5). This maximum increase in solubility and dissolution rate might be associated with sustained supersaturation, formation of nanoparticles during dissolution, crystal nucleation, and growth inhibition by Kollidon ® VA 64 (polymer shows adsorption on drug particles). Another possible mechanism involved in enhancing the solubility of this polymer could be the formation of intermolecular bonding, especially hydrogen bonding between carbonyl functional group of pyrrolidone and vinyl acetate [29] In the case of ternary systems, the formulation KP407 (TD3) exhibited drug release of 82.46 ± 0.082% and 93.20 ± 0.076% in pH 6.8 phosphate buffer and 0.1 N HCl (pH 1.2), respectively, after 120 min, and the formulation KPVP (TD3) showed drug release of 87.31 ± 0.805% and 97.60 ± 0.887% in pH 6.8 phosphate buffer and 0.1 N HCl, respectively, after 120 min. The increase in solubility and drug release in the case of Kolliphor ® P 407-based ternary dispersion might be linked to the surfactant nature of this polymer ( Figure 6). Kolliphor ® P 407 is composed of ethylene oxide and propylene oxide blocks, which are responsible for self-assembly into micelles in aqueous media, thus leading to solubilization of the drug. The mechanism by which PVP-K30 increased drug release is most likely the maintenance of supersaturation resulting from the crystal growth inhibition potential of PVP. Hydrogen bonding between PVP and the weakly basic drug may be another reason for the increased solubility as well as dissolution [29,31].
Based on the results of solubility and dissolution studies, KPVP (TD3) ternary solid dispersion formulation was considered as the optimized formulation (Figure 7).

Drug Content and % Yield
The results for drug content and percent yield are presented in Table 4. All the formulations provided more than 80% drug content and yield. Drug content and yield of all formulations ranged from 81.20 ± 0.011% to 94.56 ± 0.005% and 81.20 ± 1.085% to 94.33 ± 1.258%, respectively. Importantly, the optimized formulation KPVP (TD3) revealed 94.56 ± 0.005% drug content and 94.33 ± 1.258% yield.

Kinetic Modelling
The results of kinetic modelling analysis are shown in Tables 5 and 6. All solid dispersion formulations followed the Korsmeyer-Peppas model, as the values of R 2 for this model were higher compared to other models. Moreover, the values of n obtained from the slope of the Korsemeyer-Peppas model for all solid dispersions were less than 0.45 which shows that the drug release mechanism followed Fickian diffusion [32]. A possible explanation for this mechanism may be that the hydrophilic polymer formed a diffusion layer surrounding the drug particles leading to an alteration in the hydrophobicity of drug, increased wetting, and reduced particle size and crystallinity. Therefore, the drug had to pass through this diffusion layer in order to come in contact with dissolution medium. It is also reported from the literature that formation of such a diffusion layer by hydrophilic polymers supports this type of release behavior [33].

SEM
The SEM micrographs of pure Irbesartan and of the prepared formulations S 1 , K 4 , KP407 (TD 3 ), and KPVP (TD 3 ) are shown in Figure 8. It was found that the SEM micrograph of Irbesartan clearly exhibited needle type lumps or crystals of pure drug, thus confirming its crystalline nature [22]. S1 and K 4 formulations showed irregular amorphous forms of the drug with few needles. However, the SEM analysis of ternary dispersion KP407 (TD 3 ) confirmed almost complete transformation of crystalline API into amorphous form. In addition, the SEM micrographs of ternary dispersion KPVP (TD 3 ) showed disappearance of crystals of drug due to its masking by the polymeric carriers. These SEM results were also supported by the PXRD finding confirming the presence of the amorphous form of the drug in the optimized solid dispersion formulation [34].

PXRD Studies
The PXRD data of pure Irbesartan and other samples are provided in Figure 9. The PXRD of Irbesartan showed intense peaks at 12 [35], whereas the Soluplus ® did not show any intense peaks due to its amorphous nature [36]. In comparison, the PXRD of solid dispersion (S 1 ) with 1:1 ratio (drug: polymer) exhibited drug peaks with less intensity, reflecting its partial transformation into amorphous form [37]. Kollidon ® VA 64 showed two halos near 12 and 22 2θ [38]. The PXRD of formulation (K 4 ) with 1:4 ratio (drug: polymer) exhibited only a few drug peaks with much less intensity, thus supporting more conversion into its amorphous form [16].
Kolliphor ® P 407 showed two peaks at 19.346 • and 23.472 • angles (2 θ) [16]. Polyvinylpyrrolidone-K30 did not show these typical diffraction peaks due to its amorphous nature [39], indicating a broad and diffused pattern as its molecules are randomly arranged in a crystal lattice [40]. Furthermore, the PXRD of formulation KP407 (TD 3 ) with 1:4:3 ratio (drug: binary polymer:ternary polymer) revealed only one small peak, reflecting a high conversion of crystalline drug into amorphous form. Also, the PXRD of formulation KPVP (TD 3 ) with 1:4:3 ratio (drug: binary polymer:ternary polymer) exhibited complete transformation of the drug into amorphous form, showing no peak. S1 and K4 formulations showed irregular amorphous forms of the drug with few dles. However, the SEM analysis of ternary dispersion KP407 (TD3) confirmed al complete transformation of crystalline API into amorphous form. In addition, the micrographs of ternary dispersion KPVP (TD3) showed disappearance of crystals of due to its masking by the polymeric carriers. These SEM results were also supporte the PXRD finding confirming the presence of the amorphous form of the drug in the timized solid dispersion formulation [34].

FTIR Spectroscopy Studies
The FTIR spectra of pure Irbesartan provided peaks at 1610 cm −1 due to C-N str 1727 cm −1 due to C-O stretch, 2900 cm −1 and 2964 cm -1 due to N-H stretches, 1436 cm -1409 due to NNH bending, and 778 cm −1 due to NH out of plane bending of the C group, which are in accordance with the previous literature [22,35,41] ( Figure 10A). P at 1727 cm −1 , 1610 cm −1 , 778 cm −1 , 1517 cm −1 , and 756 cm −1 corresponds to crystalline A of Irbesartan [35,42]. The FTIR spectra of Soluplus ® showed peaks similar to those viously reported in the literature. Peaks seemingly due to O-H stretch appeared at cm −1 , C-H stretch (aromatic) at 2915 cm −1 , C=O stretch due to vinyl acetate at 1730 C=O stretch due to vinyl caprolactam carbonyl at 1630 cm −1 , and C-O-C stretch at cm −1 [43].
The prominent peaks of the API and the carrier were present in solid dispersion with lower intensity, which is indicative of no major interaction between drug and p mer. The presence of less intense and broadened peaks of drug at 2900 cm −1 and 2964 1 might be due to possible bonding between the N-H group of the drug and the carb (C=O) group of Soluplus ® [43].
The peak of drug at 1727 cm −1 appears with less intensity and the peak at 1610 cm broadened in S1 formulation. This may be due to overlapping of the drug with the p mer.
Kollidon ® VA 64 possess two hydrogen bond acceptor groups which are from carbonyl group of the pyrrolidone ring (at 1660 cm −1 ) and vinyl acetate (at 1737 cm −1 ( Figure 10B). Kollidon ® VA 64 also showed peaks at 3500 cm −1 and 2900 cm −1 , prob due to a higher number of O-H groups [44]. Moreover, the major peaks of Irbesartan

FTIR Spectroscopy Studies
The FTIR spectra of pure Irbesartan provided peaks at 1610 cm −1 due to C-N stretch, 1727 cm −1 due to C-O stretch, 2900 cm −1 and 2964 cm -1 due to N-H stretches, 1436 cm -1 and 1409 due to NNH bending, and 778 cm −1 due to NH out of plane bending of the CNH group, which are in accordance with the previous literature [22,35,41] (Figure 10A). Peaks at 1727 cm −1 , 1610 cm −1 , 778 cm −1 , 1517 cm −1 , and 756 cm −1 corresponds to crystalline form A of Irbesartan [35,42]. The FTIR spectra of Soluplus ® showed peaks similar to those previously reported in the literature. Peaks seemingly due to O-H stretch appeared at 3460 cm −1 , C-H stretch (aromatic) at 2915 cm −1 , C=O stretch due to vinyl acetate at 1730 cm −1 , C=O stretch due to vinyl caprolactam carbonyl at 1630 cm −1 , and C-O-C stretch at 1470 cm −1 [43].
The prominent peaks of the API and the carrier were present in solid dispersion (S 1 ) with lower intensity, which is indicative of no major interaction between drug and polymer. The presence of less intense and broadened peaks of drug at 2900 cm −1 and 2964 cm -1 might be due to possible bonding between the N-H group of the drug and the carbonyl (C=O) group of Soluplus ® [43].
The peak of drug at 1727 cm −1 appears with less intensity and the peak at 1610 cm −1 is broadened in S 1 formulation. This may be due to overlapping of the drug with the polymer.
Kollidon ® VA 64 possess two hydrogen bond acceptor groups which are from the carbonyl group of the pyrrolidone ring (at 1660 cm −1 ) and vinyl acetate (at 1737 cm −1 ) [13] ( Figure 10B). Kollidon ® VA 64 also showed peaks at 3500 cm −1 and 2900 cm −1 , probably due to a higher number of O-H groups [44]. Moreover, the major peaks of Irbesartan and Kollidon ® VA 64 were retained in formulation (K 4 ), showing the compatibility of the drug and polymers. Peaks that appeared at 2900 cm −1 and 2964 cm -1 were present in the formulation with less intensity. The drug peak at 1727 cm −1 in the formulation (K 4 ) was less intense compared to its appearance in the spectrum of pure drug. The drug peak that appeared at 1610 cm −1 in FTIR was shifted to the higher frequency of 1666 cm -1 . Shifting towards higher wavelengths may be due to the presence of weak Van der Waal forces between the drug and polymer [22]. This broadening of peaks was also linked to the change of drug form (crystalline to amorphous) [45]. Proton donors, such as OH, and proton acceptors are present in Kollidon ® VA 64, which might have facilitated intermolecular interaction at these sites resulting in broadening of the peaks [46]. Major peaks of PVP-K30 appeared at 2940 (C-H), 1650 (C=O stretch), 1506 (C=C stretch), and 1273 cm -1 (C-N stretch) [47]. In optimized formulation KPVP (TD 3 ), drug peaks appeared at 1610 cm −1 and 1727 cm −1 with less intensity, and peaks were broadened at 2900 cm −1 and 2964 with much less intensity, which could be due to hydrogen bonding between the carbonyl functional group of PVP and the N-H functional group of the drug [48].
In addition, Kolliphor ® P 407 showed peaks at 2893.02 cm -1 (C-H aliphatic stretching), 1342 cm -1 (O-H bending), and 1110 cm -1 (C-O stretching) [49]. In optimized KP407 (TD 3 ) formulation, drug peaks were broadened at 1610 cm -1 , 1732 cm -1 , 2900 cm -1 , and 2964 cm -1 , with less intensity in ternary dispersion. This broadening and reduction in intensity clearly reflected reduced crystallinity of the drug in the formulation [50] (Figure 11). towards higher wavelengths may be due to the presence of weak Van der Waal forces between the drug and polymer [22]. This broadening of peaks was also linked to the change of drug form (crystalline to amorphous) [45]. Proton donors, such as OH, and proton acceptors are present in Kollidon ® VA 64, which might have facilitated intermolecular interaction at these sites resulting in broadening of the peaks [46]. Major peaks of PVP-K30 appeared at 2940 (C-H), 1650 (C=O stretch), 1506 (C=C stretch), and 1273 cm -1 (C-N stretch) [47]. In optimized formulation KPVP (TD3), drug peaks appeared at 1610 cm −1 and 1727 cm −1 with less intensity, and peaks were broadened at 2900 cm −1 and 2964 with much less intensity, which could be due to hydrogen bonding between the carbonyl functional group of PVP and the N-H functional group of the drug [48]. In addition, Kolliphor ® P 407 showed peaks at 2893.02 cm -1 (C-H aliphatic stretching), 1342 cm -1 (O-H bending), and 1110 cm -1 (C-O stretching) [49]. In optimized KP407 (TD3) formulation, drug peaks were broadened at 1610 cm -1 , 1732 cm -1 , 2900 cm -1 , and 2964 cm -1 , with less intensity in ternary dispersion. This broadening and reduction in intensity clearly reflected reduced crystallinity of the drug in the formulation [50] (Figure 11).

DSC Studies
The DSC thermograms of pure drug, polymers, and formulations are shown in Figure 12. Pure Irbesartan depicted an intense endothermic peak at 190 °C due to its melting point which was shifted in solid dispersion formulations, indicating reduced crystallinity of pure drug in formulations [50,51]. The presence of a broader peak, or the complete absence of a melting peak, is a clear indication that a drug is partially or completely dispersed in polymeric carriers [52]. In contrary, Soluplus ® did not show any melting endothermic peak due to its amorphous nature [9]. It was noticed that the drug peak was broadened (170-184 °C) in the DSC curve of solid dispersion (S1) reflecting its partial dis-

DSC Studies
The DSC thermograms of pure drug, polymers, and formulations are shown in Figure 12. Pure Irbesartan depicted an intense endothermic peak at 190 • C due to its melting point which was shifted in solid dispersion formulations, indicating reduced crystallinity of pure drug in formulations [50,51]. The presence of a broader peak, or the complete absence of a melting peak, is a clear indication that a drug is partially or completely dispersed in polymeric carriers [52]. In contrary, Soluplus ® did not show any melting endothermic peak due to its amorphous nature [9]. It was noticed that the drug peak was broadened (170-184 • C) in the DSC curve of solid dispersion (S 1 ) reflecting its partial dispersion in polymeric carrier. Furthermore, Kollidon ® VA 64 did not reveal any sharp melting endothermic peak due to its amorphous nature [44]. In the DSC curve of formulation (K 4 ), the drug peak was shifted towards lower temperature (110-140 • C), supporting the partial conversion of the drug into its amorphous form. These results are in accordance with FTIR and XRD results. Kolliphor ® P 407 exhibited an endothermic peak at 56 • C [53]. The thermogram of KP407 (TD 3 ) formulation showed complete absence of a drug melting peak. PVP K30 provided a broad endothermic peak (70-130 • C) due to its amorphous nature. However, the DSC curve of KPVP (TD 3 ) revealed a complete disappearance of drug peak, supporting its conversion into amorphous form [54]. persion in polymeric carrier. Furthermore, Kollidon ® VA 64 did not reveal any sharp melting endothermic peak due to its amorphous nature [44]. In the DSC curve of formulation (K4), the drug peak was shifted towards lower temperature (110-140 °C), supporting the partial conversion of the drug into its amorphous form. These results are in accordance with FTIR and XRD results.
Kolliphor ® P 407 exhibited an endothermic peak at 56 °C [53]. The thermogram of KP407 (TD3) formulation showed complete absence of a drug melting peak. PVP K30 provided a broad endothermic peak (70-130 °C) due to its amorphous nature. However, the DSC curve of KPVP (TD3) revealed a complete disappearance of drug peak, supporting its conversion into amorphous form [54].

Conclusions
In this research, binary and ternary solid dispersion-based formulations of Irbesartan were successfully formulated and evaluated. Clearly, the results showed that all the prepared formulations provided a significant increase in solubility as well as dissolution, however, the performance of ternary solid dispersions were potentially more effective when compared to binary solid dispersions. Moreover, the characterization data of FTIR, DSC, SEM, and XRD studies revealed the amorphous nature of the drug in the prepared solid dispersions. Finally, it was concluded that the prepared solid dispersion formulations could be potentially used to increase the solubility as well as dissolution of poorly soluble Irbesartan. Institutional Review Board Statement: Not applicable as animals were not involved in this study.
Informed Consent Statement: Not applicable as humans were not involved in this study.

Data Availability Statement:
The data presented in this study are available on request from the corresponding author. The data are not publicly available as it was originally produced through research.